Alnylam Pharmaceuticals develops RNA interference (RNAi) medicines that silence disease-causing genes, spanning discovery, development, manufacturing and commercialization from its Cambridge, Massachusetts base.
Alnylam Pharmaceuticals is a biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. It describes itself as the world's leading developer of RNA interference (RNAi) therapeutics - medicines designed to treat disease by silencing the genes that cause it - and works across the full arc of the business, from discovery and development through manufacturing and commercialization. The company employs more than 1,900 people globally and maintains commercial operations spanning multiple continents.
Its scientific focus covers RNAi therapeutics, gene silencing and genetic medicine, with particular attention to rare diseases. The pipeline includes RNAi-based medicines directed at transthyretin (TTR) amyloidosis, acute hepatic porphyria and primary hyperoxaluria. Alnylam has been advancing RNAi science for more than two decades, and operates as an independent biopharmaceutical company within the biotechnology, rare-disease and genetic-medicine sectors.
For legal practitioners, the relevant context is the range of activity under one roof: research and development, biopharmaceutical manufacturing, and the commercialization of therapeutics across international markets. The company describes its culture as award-winning and mission-driven, oriented around scientific excellence and the delivery of transformational medicines for patients. Further information is available at alnylam.com.